Tags |
|
|
Links |
|
|
E-Folder - Startups Must Choose Financing Models Wisely: Bootstrapping versus Angels versus VCs
When a Startup decides to expand using Bootstrapping, Angels, or VCs, it is incorrectly assumed that this choice has to do solely with money. Many advise founders to take the best deal and get the process over with as soon as possible.
However, it must be noted that the type of financing Startups receive determines the company’s strategic direction and probability of su
However, it must be noted that the type of financing Startups receive determines the company’s strategic direction and probability of su
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ccess.
Finance Models have numerous tangible strategic implications. When early stage Startups choose a Finance Model, they are confining themselves to a limited range of strategic options. When choosing a Finance Model, I think it is best to momentarily forget about money and focus sensibly on strategy.
To make the best possible decisions regarding your financing and
Finance Models have numerous tangible strategic implications. When early stage Startups choose a Finance Model, they are confining themselves to a limited range of strategic options. When choosing a Finance Model, I think it is best to momentarily forget about money and focus sensibly on strategy.
To make the best possible decisions regarding your financing and
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
e facto strategic direction, Startups have to place themselves in the best possible situation from day one.
Every Startup should end a series of successful prototyping with an analysis of which low-cost, high-impact business models, revenue models, pricing models, and sales strategies are suitable for their solution [problem-solving product or service] and its Users.
T
Every Startup should end a series of successful prototyping with an analysis of which low-cost, high-impact business models, revenue models, pricing models, and sales strategies are suitable for their solution [problem-solving product or service] and its Users.
T
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
he next step is for Startups to assess the cost of implementing and executing particular business models. Startups may choose to self-finance these costs, receive funds from Angels, or use a pay-as-you-go strategy where you use a small base of sales to generate free cash flow which in turn funds additional sales efforts.
Finally, when moving into Alpha and Beta testing,
Finally, when moving into Alpha and Beta testing,
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
it its critical to simultaneously test well-thought out business models, revenue models, pricing models, and sales strategies alongside your solution. If you decide to chase market share, forget about business models, and give your product away for the interim, then it is still a good idea to enable Users to purchase upgrades, subscriptions, or ancillaries. Otherwise, yo
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
u may never know how many Users are committed or passive.
The Bootstrap Finance Model necessitates laser beam focus on product development, cost control, sales, and profits. Bootstrapping is akin to the concept of intelligent design. You are building a company from the bottom-up and are willing to allow a naturalistic growth cycle to occur. You’re interested in keeping
The Bootstrap Finance Model necessitates laser beam focus on product development, cost control, sales, and profits. Bootstrapping is akin to the concept of intelligent design. You are building a company from the bottom-up and are willing to allow a naturalistic growth cycle to occur. You’re interested in keeping
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
our company very malleable, ready to shift directions in accord with market demands. You are opportunistic. Bootstrapping has lower initial risks, but higher long term risks since you may lose significant market share while other companies choose to Go Big. Bootstrappers risk being relegated to a sub par market position even though you probably have hip solutions, the co
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
olest brands, and a cult-like User base.
The Angel Finance Model requires smooth investor relations, a high User growth rate, and a strategic direction that leads towards a highly probable merger or acquisition. Angel financing is similar to evolutionary theory. The Angel’s funds act as a propulsive agent to thrust a Startup upon an evolutionary cycle towards a probable
The Angel Finance Model requires smooth investor relations, a high User growth rate, and a strategic direction that leads towards a highly probable merger or acquisition. Angel financing is similar to evolutionary theory. The Angel’s funds act as a propulsive agent to thrust a Startup upon an evolutionary cycle towards a probable
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
Series A round or additional infusions of capital by Angels.
Despite opinions to the contrary, Angel investors are not charities, repositories of free money, or blind speculators panning for gold in quicksand. Angels need to make successful investments to sustain their investment activity. Angel financing has medium short term and medium long term risk.
The biggest dil
Despite opinions to the contrary, Angel investors are not charities, repositories of free money, or blind speculators panning for gold in quicksand. Angels need to make successful investments to sustain their investment activity. Angel financing has medium short term and medium long term risk.
The biggest dil
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
emma in the Startup/Angel relationship is a misunderstanding of roles and responsibilities. Angels essentially invest in early stage conceptual renderings of solutions. Angels have to avoid getting involved in day to day management. Their only concern should be the completion of a workable solution [problem-solving product or service] that is ready to grow from prototype
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
to Alpha tests/Beta tests. With Angels the clock is ticking slowly, but it is ticking. There is an expectation of multiple rounds of financing and merger or acquisition within 3-5 years. An Angel usually expects to earn a post-dilution return on investment of at least 200%.
The VC Finance Model can be simplified and best understood as a troika comprised of Seed Stage VC
The VC Finance Model can be simplified and best understood as a troika comprised of Seed Stage VC
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
Funding, Early Stage VC Funding, and Late Stage VC Funding. Seed Stage VCs invest after evaluating an early prototype or hearing a particularly interesting pitch. Early Stage VCs invest with the sole intent of maximizing the value and market position of a Startup in anticipation of future rounds of financing. Late Stage VCs invest in Startups seeking additional funding w
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
hile preparing for an eventual IPO or M&A. At each stage of a Startups’ evolution, VCs invest with the expectation that exponential growth and a successful M&A or IPO will substantiate the risks incurred.
The VC Financing Model compels a startup to grow at an ever accelerating pace. Such growth comes at considerable risk and entails the development of a costly labor, ad
The VC Financing Model compels a startup to grow at an ever accelerating pace. Such growth comes at considerable risk and entails the development of a costly labor, ad
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ertising, and technology infrastructure. Over the short term the risks involve technology and labor. The Startup must scale quickly to ensure quality user interactions, while priming their web sites and customer service systems to handle an exponential increase in Users. The Startup has to also deal with potential shortages in highly skilled programmers and project manag
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
ers. Long term risks are market based. While managing such a fast pace of expansion, the Startup must stay grounded in the marketplace and respond proactively to shifts in the tastes and need of their Users.
Under this scenario, the focus is placed on expanding market share and brand identity. Typically, VCs expect to net a return on investment of at least 600%-1000%. S
Under this scenario, the focus is placed on expanding market share and brand identity. Typically, VCs expect to net a return on investment of at least 600%-1000%. S
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
artups funded by VCs are always expected to become market leaders. A VC funded software company surviving multiple rounds of financing and heading towards a M&A or IPO can easily spend $50,000,000 or more over a two year period.
It is important to note that while there are innumerable examples of surviving and thriving Bootstrapped and Angel financed companies, successf
It is important to note that while there are innumerable examples of surviving and thriving Bootstrapped and Angel financed companies, successf
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ul Large-Scale VC investments are short in number in the Web 2.0 Era. Startups don’t require that much money to fund operations. And there is a more patient attitude on the part of Startup Founders who appear to be committed to running their companies for long periods of time before seeking VC funding.
Many Startups will become sustainable using all three Financing Mode
Many Startups will become sustainable using all three Financing Mode
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
s in the near future. A number of Startup Founders will decide early on to exclusively rely on one Financing Model throughout the embryonic period of their company. For example, it is possible that a Startup could reach a successful M&A or IPO exit by the sole means of Bootstrapping. To the contrary, numerous Startups will solely utilize several Angel investments or mult
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
iple rounds of VC funding to reach success.
Furthermore, others will undoubtedly find success by mixing and matching Financing Models. For example, a Startup may initially secure Angel investments then choose to Bootstrap or accept VC funding to facilitate further expansion and progress towards exit.
It is best to remain free of any preconceived notions or biases. When
Furthermore, others will undoubtedly find success by mixing and matching Financing Models. For example, a Startup may initially secure Angel investments then choose to Bootstrap or accept VC funding to facilitate further expansion and progress towards exit.
It is best to remain free of any preconceived notions or biases. When
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
the time comes to make a Financing Model decision, just remember you’re making a compulsory strategic decision. Just make the best decision possible relative to the market conditions and fiscal circumstances that face your company at that time.
MORE ESSAYS ARE VIEWABLE AT: http://www.geraldjoseph.typepad.com
MORE ESSAYS ARE VIEWABLE AT: http://www.geraldjoseph.typepad.com
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.e-folder.org.ua/article/46595/e-folder-Startups-Must-Choose-Financing-Models-Wisely-Bootstrapping-versus-Angels-versus-VCs.html">Startups Must Choose Financing Models Wisely: Bootstrapping versus Angels versus VCs</a>
BB link (for phorums):
[url=http://www.e-folder.org.ua/article/46595/e-folder-Startups-Must-Choose-Financing-Models-Wisely-Bootstrapping-versus-Angels-versus-VCs.html]Startups Must Choose Financing Models Wisely: Bootstrapping versus Angels versus VCs[/url]
Related Articles:
How To Out-Market The Big Guys
A Recipe For Selling Success and Baja Fish Tacos
Bookmark it:
|